Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Alendronate Osteoporosis Study

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified January 2006 by Boston Children’s Hospital.
Recruitment status was:  Active, not recruiting
Glaser Pediatric Research Network
Elizabeth Glaser Pediatric AIDS Foundation
Information provided by:
Boston Children’s Hospital Identifier:
First received: July 7, 2005
Last updated: January 13, 2006
Last verified: January 2006
This trial will test the hypothesis that among 20 children and adolescents from Children's Hospital, Boston with Crohn’s disease, ulcerative colitis, systemic-onset juvenile rheumatoid arthritis, juvenile dermatomyositis, systemic lupus erythematosus, mixed connective tissue disease and vasculitis, treatment of glucocorticoid-associated osteopenia and osteoporosis with 18 months of alendronate (FOSAMAX®, Merck & Co., Inc.) will result in greater improvement in the mean change of individual AP spine bone mineral density (BMD) (gm/cm2) determined by dual energy X-ray absorptiometry (DXA) than treatment with 18 months of standard of care therapy.

Condition Intervention Phase
Glucocorticoid-Associated Osteopenia and Osteoporosis
Drug: Alendronate
Phase 2
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Factorial Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Official Title: Double-Blinded Controlled Trial of Alendronate for the Treatment of Childhood and Adolescent Glucocorticoid- Associated Osteopenia and Osteoporosis

Resource links provided by NLM:

Further study details as provided by Boston Children’s Hospital:

Primary Outcome Measures:
  • To test the hypothesis that among children and adolescents with Crohn’s disease, ulcerative colitis, systemic-onset juvenile rheumatoid arthritis, juvenile dermatomyositis, systemic lupus erythematosus, mixed connective tissue disease and vasculitis, tr

Secondary Outcome Measures:
  • Alternate outcome measures
  • Comparison of DXA and QCT
  • Predictors for response to alendronate
  • Growth velocity
  • Fracture assessment

Estimated Enrollment: 20
Study Start Date: March 2003

Ages Eligible for Study:   8 Years to 22 Years   (Child, Adult)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Subjects must be diagnosed with either ulcerative colitis, Crohn’s disease, systemic-onset juvenile rheumatoid arthritis, juvenile dermatomyositis, systemic lupus erythematosus (SLE), mixed connective tissue disease (MCTD) or vasculitis according to standard criteria where available, and according to treating physicians when not available.
  • Subjects must have diminished AP lumbar spine (L1-L4) BMD by DXA (Hologic 4500) with a Z score ≤ –1.5 SD assessed within 8 weeks of the Baseline Visit.
  • Subjects must have received daily, alternate day or weekly systemic glucocorticoid therapy for a minimum of six months total in their life-time.
  • Subjects must be between the ages of 8 and 21 years, 11 months, at randomization. Although subjects younger than 8 years of age may be affected by osteoporosis, limited normative data prevents assignment of a BMD Z score for this group.
  • Regarding subjects with child-bearing potential Females who have had at least one menstrual cycle must either be abstinent or must be using an effective method of birth control.

Exclusion Criteria:

  • Current or recent (within 6 months) treatment with therapeutic doses of a bisphosphonate, calcitonin, human growth hormone, and heparin, all agents known to alter bone density
  • A history of recent (within one year of screening) major upper gastrointestinal (GI) disease (above the jejunum), including, but not limited to, peptic ulcer, esophageal disease or active GI bleeding, or ever had surgery of the upper GI tract other than pyloroplasty. A history of abnormalities of the esophagus which delay esophageal emptying, such as stricture or achalasia
  • Hyperthyroidism (suppressed thyroid stimulating hormone (TSH) and elevated free thyroxine (T4)), hyperparathyroidism (elevated parathyroid hormone (PTH)), malignancy, rickets, or osteomalacia (by history), all assessed within 8 weeks of the Baseline Visit.
  • 25 (OH) vitamin D below 20 mg/L
  • Planned or current pregnancy and/or breastfeeding
  • Renal dysfunction defined as dependence on dialysis or a creatinine clearance < 35 ml/min, assessed within 4 weeks of the Baseline Visit. Creatinine clearance = [(height in cm x 0.55)/plasma creatinine] for all females and for males < 13 years old; [(height in cm x 0.70)/plasma creatinine] for males ³ 13 years old.
  • Hepatic insufficiency defined as SGPT or SGOT greater than twice normal for age, assessed within 4 weeks of the Baseline Visit.
  • Uncorrected hypocalcemia (ionized calcium>10% below age-adjusted range), assessed within 4 weeks of the Baseline Visit
  • Known or suspected hypersensitivity to bisphosphonates
  • Inability to follow instructions for dosing, including being unable to swallow the study medication with plain water first thing in the morning, stand or sit upright without any other food or beverage for at least 30 minutes following dosing and until their next meal
  • Weight greater than 136 kg (300 lb), as the DXA is not reliable for subjects of this size
  • Weight less than 17 kg (37 lb), assessed within 8 weeks of the Baseline Visit
  • Permanent foreign body (prosthetic, surgical clips, permanent earring/umbilical ring) in region of results of the study
  • Enrollment Procedures interest, or soft tissue calcinosis overlying the region of interest
  • Inability to undergo dual energy X-ray absorptiometry or CT scan
  • Developmental or cognitive delay which may interfere with cooperation and/or compliance with the procedures
  • Subject expects to move out of the area during the study period, rendering follow-up per protocol impractical
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00277251

Sponsors and Collaborators
Boston Children’s Hospital
Glaser Pediatric Research Network
Elizabeth Glaser Pediatric AIDS Foundation
Principal Investigator: Catherine Gordon, MD Boston Children’s Hospital
  More Information Identifier: NCT00277251     History of Changes
Other Study ID Numbers: 04-12-187R 
Study First Received: July 7, 2005
Last Updated: January 13, 2006
Health Authority: United States: Food and Drug Administration

Keywords provided by Boston Children’s Hospital:
Crohn’s disease
systemic-onset juvenile rheumatoid arthritis
juvenile dermatomyositis
systemic lupus erythematosus (SLE)
Mixed connective tissue disease (MCTD)

Additional relevant MeSH terms:
Bone Diseases, Metabolic
Bone Diseases
Musculoskeletal Diseases
Bone Density Conservation Agents
Physiological Effects of Drugs processed this record on December 09, 2016